MarketCap
Facebook
X
TelegramOsmotica Pharmaceuticals plc General and Administrative Expenses 2011-2026 | OSMT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Osmotica Pharmaceuticals plc
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 82 M | 93 M | 74.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93 M | 74.2 M | 83.1 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B |  USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 0.9 | -2.33 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
488 M | $ 21.96 | -0.68 % | $ 3.64 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Aligos Therapeutics
ALGS
|
20.7 M | $ 6.4 | 4.4 % | $ 63.3 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 21.41 | 1.9 % | $ 1 B | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
5.78 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
4.51 M | $ 12.26 | 3.72 % | $ 1.62 B |  Australia |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
7.16 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 105.46 | -0.09 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
3.65 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.08 | 0.25 % | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 23.26 | 1.75 % | $ 2.96 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.44 | -5.88 % | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 2.91 | -1.36 % | $ 4.79 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
bluebird bio
BLUE
|
166 M | - | - | $ 546 M | USA |
 |
ContraFect Corporation
CFRX
|
12.2 M | - | -5.16 % | $ 5.39 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
28.3 M | $ 6.84 | 2.7 % | $ 195 M | USA |
 |
BioXcel Therapeutics
BTAI
|
20.5 M | $ 1.06 | -3.64 % | $ 12.9 M | USA |
 |
Cabaletta Bio
CABA
|
29.6 M | $ 2.95 | -3.28 % | $ 296 M | USA |
 |
Cara Therapeutics
CARA
|
8.74 M | - | -3.03 % | $ 260 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |